Executive Vice President, Chief Operating Officer · Intellia Therapeutics, Inc. (NTLA)

Andrew Schiermeier

A named executive officer of Intellia Therapeutics in every fiscal year CompBrief holds from FY2018 to FY2020. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2020

$1,718,528

Salary $455,400Stock awards $0Bonus $173,052

FY2019: $1,227,875

3rd of 5 named executive officers at Intellia Therapeutics by FY2020 total.

5 named officers on file for Intellia Therapeutics, FY2020

Andrew Schiermeier’s pay file — $29

  • 3 fiscal years of pay, line by line
  • 6 equity grants, each cited to its filing
  • NTLA’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Intellia Therapeutics’s whole pay program stands against its peers

  • Intellia Therapeutics’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on NTLA→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 28, 2021 (DEF 14A).

Free

Get Andrew Schiermeier’s full pay file as a PDF — free

More than this page: up to 10 years of Andrew’s pay history, a side-by-side peer comparison, and a one-page board summary — the whole file, yours now and by email.

Andrew Schiermeier compensation by year

Intellia Therapeutics Summary Compensation Table · all 3 fiscal years held
In US dollars, as Intellia Therapeutics reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2018FY2019FY2020
Salary$408,934$440,000$455,400
Bonus$182,600$167,200$173,052
Stock awards$295,550$0$0
Option awards$2,028,554$611,897$1,081,148
Non-equity incentive$0$0$0
Pension and deferred compensation$0$0$0
All other$9,668$8,778$8,928
Total$2,925,306$1,227,875$1,718,528

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Intellia Therapeutics, Inc. DEF 14A filed April 28, 2021, accession 0001564590-21-021413, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Intellia Therapeutics, Inc. filed document, accession 0001564590-21-021413. Every figure is read from that document and cited to the page and table it appears in. Filed April 28, 2021.

$2.9M
$1.2M
$1.7M
FY18
FY19
FY20
SalaryBonusStock awardsOption awardsAll other

Equity holdings

unvested awards at FY2020 year-end
TypeUnvested unitsValue at year-endExercise price
Option36,667—$18.09
Option40,500—$14.58
Option8,323—$20.56
Option3,125—$13.48
Option135,000—$13.40
Option6,875—$18.30

Per the Outstanding Equity Awards at Fiscal Year-End table in Intellia Therapeutics, Inc.'s FY2020 proxy; value at the fiscal year-end close, as the company printed it.

Intellia Therapeutics’s named executive officers, FY2020

as the company reported each
Named executive officerRoleFY2020 total
John LeonardPresident, Chief Executive Officer$3,635,676
David LebwohlExecutive Vice President, Chief Medical Officer .$2,078,788
Andrew Schiermeier · this pageExecutive Vice President, Chief Operating Officer$1,718,528
Laura Sepp-LorenzinoExecutive Vice President, Chief Scientific Officer$1,690,526
Glenn GoddardExecutive Vice President, Chief Financial Officer and Treasurer$1,563,511

The full Intellia Therapeutics compensation record

free company brief

This page is one person within Intellia Therapeutics's record. The company brief lists every named executive, each linking to their own page.

Peer companies

named in the Intellia Therapeutics proxy · each links to its own free brief

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Intellia Therapeutics's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Andrew Schiermeier's compensation dossier · One-time report. No refunds.